| Symbol | CNSP |
|---|---|
| Name | CNS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2100 WEST LOOP SOUTH,SUITE 900, HOUSTON, Texas, 77027, United States |
| Telephone | +1 800 946-9185 |
| Fax | — |
| — | |
| Website | https://www.cnspharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001729427 |
| Description | CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Additional info from NASDAQ: |
(50% Neutral) CNS PHARMACEUTICALS, INC. (CNSP) Announces Business Combination
Read moreCNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
Read moreNew Form 10-K/A - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001683168-26-003374 <b>Size:</b> 723 KB
Read moreNew Form SCHEDULE 13G - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001193125-26-161735 <b>Size:</b> 155 KB
Read moreCNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Read more(85% Positive) CNS PHARMACEUTICALS, INC. (CNSP) Announces Regulatory Update
Read moreFaulkner Eric 🟢 acquired 9.5K shares (1 derivative) of CNS Pharmaceuticals, Inc. (CNSP) Transaction Date: Mar 02, 2026 | Filing ID: 001491
Read moreNew Form 3 - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-04 <b>AccNo:</b> 0001683168-26-001490 <b>Size:</b> 8 KB
Read moreNew Form 3 - CNS Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-04 <b>AccNo:</b> 0001683168-26-001488 <b>Size:</b> 8 KB
Read moreCNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04762069 | A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | Phase2 | Glioblastoma Multiforme, Adult | Active_Not_Recruiting | 2021-05-18 | 2026-07-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Lomustine | Other | Phase PHASE2 | Glioblastoma Multiforme, Adult | ACTIVE_NOT_RECRUITING | NCT04762069 |
| Berubicin | Other | Phase PHASE2 | Glioblastoma Multiforme, Adult | ACTIVE_NOT_RECRUITING | NCT04762069 |
| Placebo | DRUG | Phase PHASE3 | Clear Cell Renal Carcinoma | TERMINATED | NCT01599754 |
| Axitinib | DRUG | Phase PHASE3 | Clear Cell Renal Carcinoma | TERMINATED | NCT01599754 |
| abituzumab | DRUG | Phase PHASE2 | Metastatic Colorectal Cancer | WITHDRAWN | NCT03688230 |
| Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment) | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment) | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment) | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment) | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 1000 mg or Placebo | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 300 mg or Placebo | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bentracimab (PB2452) 100 mg or Placebo | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT05162131 |
| Bortezomib | DRUG | Phase PHASE1 | Neuroblastoma Recurrent | COMPLETED | NCT02139397 |
| Bentracimab (PB2452) Infusion | DRUG | Phase PHASE3 | Hemorrhage | COMPLETED | NCT04286438 |
| Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT03928353 |
| Ticagrelor Oral Tablet - Pre-Treatment | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT03928353 |
| Placebo - Sodium Chloride | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT03928353 |
| PB2452 Infusion | DRUG | Phase PHASE2 | Healthy | COMPLETED | NCT03928353 |
| eflornithine HCl | DRUG | Preclinical | Neuroblastoma | AVAILABLE | NCT03581240 |
| DFMO | DRUG | Phase PHASE2 | Neuroblastoma | COMPLETED | NCT02395666 |
| vorinostat | DRUG | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT02559778 |
| sorafenib | DRUG | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT02559778 |
| dasatinib | DRUG | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT02559778 |
| Ceritinib | DRUG | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT02559778 |
| Lomustine | DRUG | Phase PHASE2 | Glioblastoma Multiforme, Adult | ACTIVE_NOT_RECRUITING | NCT04762069 |
| Berubicin | DRUG | Phase PHASE2 | Glioblastoma Multiforme, Adult | ACTIVE_NOT_RECRUITING | NCT04762069 |